Cytotoxic effects of activated alveolar macrophages on lung carcinoma cells via cell-to-cell contact and nitric oxide

Anticancer Research

Volumn 30, Issue 8, 2010, Pages 3135-3141

  Sawachi, Keiichi ^a   Shimada, Yasuteru ^a   Taniguchi, Hiroaki ^a   Hirota, Keiji ^a   Inagawa, Hiroyuki ^a,b   Kohchi, Chie ^a,b   Soma, Gen Ichiro ^a,b,c   Makino, Kimiko ^a   Terada, Hiroshi ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

^c TOKUSHIMA BUNRI UNIVERSITY   (Japan)

Author keywords

Alveolar macrophage; Cell to cell contact; Lipopolysaccharide; Lung cancer; Nitric oxide; Pulmonary inhalation

Indexed keywords

LIPOPOLYSACCHARIDE; METHYLISOTHIOUREA SULFATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CONTACT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG ALVEOLUS MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RAT; ADENOCARCINOMA; ANIMAL; BIOSYNTHESIS; CELL COMMUNICATION; CELL DIVISION; COCULTURE; DRUG ANTAGONISM; IMMUNOLOGY; LUNG TUMOR; MACROPHAGE ACTIVATION; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CELL COMMUNICATION; CELL DIVISION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; HUMANS; LIPOPOLYSACCHARIDES; LUNG NEOPLASMS; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; NITRIC OXIDE; RATS;

EID: 77957352770     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Doyle A, Martin WJ, Funa K, Gazdar A, Carney D, Martin SE, Linnoila I, Cuttitta F, Mulshine J, Bunn P and Minna J: Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med 161: 1135-1151, 1985. (Pubitemid 15011330)
2. Auger M and Ross J: The Biology of Macrophages. Oxford, Oxford University Press, 1992.
3. Gordon S: Alternative activation of macrophages. Nat Rev Immunol 3: 23-35, 2003.
4. Condeelis J and Pollard JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124: 263-266, 2006.
5. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A and Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677-686, 2004.
6. Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Tachibana M, Suzuki N, Inoue M, Soma G and Nagasue N: The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res 23: 5015-5022, 2003.
7. Ohno S, Ohno Y, Suzuki N, Kamei T, Koike K, Inagawa H, Kohchi C, Soma G and Inoue M: Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res 24: 3335-3342, 2004.
8. Kohchi C, Inagawa H, Hino M, Oda M, Nakata K, Yoshida A, Hori H, Terada H, Makino K, Takiguchi K and Soma G: Utilization of macrophages in anticancer therapy: the macrophage network theory. Anticancer Res 24: 3311-3320, 2004.
9. Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Tachibana M, Ohno Y, Suzuki N, Inoue M, Soma G and Nagasue N: Role of tumor-associated macrophages (TAM) in advanced gastric carcinoma: the impact on FasL-mediated counterattack. Anticancer Res 25: 463-470, 2005. (Pubitemid 40470051)
10. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC and Balkwill FR: 'Re-educating' tumor-associated macrophages by targeting NF-κB. J Exp Med 205: 1261-1268, 2008.
11. Watkins SK, Egilmez NK, Suttles J and Stout RD: IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol 178: 1357-1362, 2007.
12. Taniguchi H, Shimada Y, Sawachi K, Hirota K, Inagawa H, Kohchi C, Soma GI, Makino K and Terada H: Lipopolysaccharide-activated alveolar macrophages having cytotoxicity against lung tumor cells through cell-to-cell binding-dependent mechanism. Anticancer Res 30: 3159-3166, 2010.
13. Akira S, Takeda K and Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2: 675-680, 2001. (Pubitemid 32747155)
14. Hirschfeld M, Weis JJ, Toshchakov V, Salkowski CA, Cody MJ, Ward DC, Qureshi N, Michalek SM and Vogel SN: Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect Immun 69: 1477-1482, 2001. (Pubitemid 32187597)
15. Godowski PJ: A smooth operator for LPS responses. Nat Immunol 6: 544-546, 2005.
16. Engelhardt R, Mackensen A and Galanos C: Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res 51: 2524-2530, 1991.
17. Otto F, Schmid P, Mackensen A, Wehr U, Seiz A, Braun M, Galanos C, Mertelsmann R and Engelhardt R: Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J Cancer 32A: 1712-1718, 1996.
18. Schmidt HHHW and Walter U: NO at work. Cell 78: 919-925, 1994.
19. Sveinbjornsson B, Olsen R, Seternes OM and Seljelid R: Macrophage cytotoxicity against murine meth A sarcoma involves nitric oxide-mediated apoptosis. Biochem Biophys Res Commun 223: 643-649, 1996.
20. Decker T, Lohmann-Matthes ML and Gifford GE: Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol 138: 957-962, 1987.
21. Decoster E, Vanhaesebroeck B, Vandenabeele P, Grooten J and Fiers W: Generation biological characterization of membrane-bound, uncleavable tumor necrosis factor. J Biol Chem 270: 18473-18478, 1995.
22. Denicola A, Souza JM, Radi R and Lissi E: Nitric oxide diffusion in membranes determined by fluorescence quenching. Arch Biochem Biophys 328: 208-212, 1996. (Pubitemid 26108188)
23. Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, Parejo NA, Pribble JP and Lemke JH: Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 180: 1584-1589, 1999.
24. Dobrovolskaia MA and Vogel SN: Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect 4: 903-914, 2002.
25. Re F and Strominger JL: Heterogeneity of TLR-induced responses in dendritic cells: from innate to adaptive immunity. Immunobiology 209: 191-198, 2004.
26. Albina JE, Cui S, Mateo RB and Reichner JS: Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J Immunol 150: 5080-5085, 1993.
27. Weiss SJ: Tissue destruction by neutrophils. N Engl J Med 320: 365-376, 1989.
28. Hino M, Kohchi C, Nishizawa T, Yoshida A, Nakata K, Inagawa H, Hori H, Makino K, Terada H and Soma G: Innate-immune therapy for lung carcinoma based on tissue-macrophage activation with lipopolysaccharide. Anticancer Res 25: 3747-3754, 2005.
29. Nagai S: Nonspecific in vitro cytotoxicity of activated human macrophages on human tumor cells. Acta Obstet Gynaecol Jpn 32: 2027-2036, 1980.
30. Kohchi C, Inagawa H, Nishizawa T, Yamaguchi T, Nagai S and Soma G: Applications of lipopolysaccharide derived from Pantoea agglomerans (IP-PA1) for health care based on macrophage network theory. J Biosci Bioeng 102: 485-496, 2006.
31. Inagawa H, Nishizawa T, Yoshioka N, Taniguchi Y, Kohchi C and Soma GI: Preventative and therapeutic potential of lipopolysaccharide derived from edible Gram-negative bacteria to various diseases. Curr Drug Ther 3: 26-32, 2008. (Pubitemid 351223160)
32. Goto S, Sakai S, Kera J, Suma Y, Soma GI and Takeuchi S: Intradermal administration of lipopolysaccharide in treatment of human cancer. Cancer Immunol Immunother 42: 255-261, 1996.
33. Inagawa H, Nishizawa T, Noguchi K, Minamimura M, Takagi K, Goto S, Soma G and Mizuno D: Antitumor effect of lipopolysaccharide by intradermal administration as a novel drug delivery system. Anticancer Res 17: 2153-2158, 1997.